Search

Your search keyword '"Karawajew, L."' showing total 253 results
Start Over Author "Karawajew, L."
253 results on '"Karawajew, L."'

1. An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: An I-BFM-FLOW-network report

Author

Maurer-Granofszky, M, Schumich, A, Buldini, B, Gaipa, G, Kappelmayer, J, Mejstrikova, E, Karawajew, L, Rossi, J, Suzan, A, Agriello, E, Anastasiou-Grenzelia, T, Barcala, V, Barna, G, Batinic, D, Bourquin, J, Bruggemann, M, Bukowska-Strakova, K, Burnusuzov, H, Carelli, D, Deniz, G, Dubravcic, K, Feuerstein, T, Gaillard, M, Galeano, A, Giordano, H, Gonzalez, A, Groeneveld-Krentz, S, Hevessy, Z, Hrusak, O, Iarossi, M, Jakso, P, Prevodnik, V, Kohlscheen, S, Kreminska, E, Maglia, O, Malusardi, C, Marinov, N, Martin, B, Moller, C, Nikulshin, S, Palazzi, J, Paterakis, G, Popov, A, Ratei, R, Rodriguez, C, Sajaroff, E, Sala, S, Samardzija, G, Sartor, M, Scarparo, P, Sedek, L, Slavkovic, B, Solari, L, Svec, P, Szczepanski, T, Taparkou, A, Torrebadell, M, Tzanoudaki, M, Varotto, E, Vernitsky, H, Attarbaschi, A, Schrappe, M, Conter, V, Biondi, A, Felice, M, Campbell, M, Kiss, C, Basso, G, Dworzak, M, Maurer-Granofszky M., Schumich A., Buldini B., Gaipa G., Kappelmayer J., Mejstrikova E., Karawajew L., Rossi J., Suzan A. C., Agriello E., Anastasiou-Grenzelia T., Barcala V., Barna G., Batinic D., Bourquin J. -P., Bruggemann M., Bukowska-Strakova K., Burnusuzov H., Carelli D., Deniz G., Dubravcic K., Feuerstein T., Gaillard M. I., Galeano A., Giordano H., Gonzalez A., Groeneveld-Krentz S., Hevessy Z., Hrusak O., Iarossi M. B., Jakso P., Prevodnik V. K., Kohlscheen S., Kreminska E., Maglia O., Malusardi C., Marinov N., Martin B. M., Moller C., Nikulshin S., Palazzi J., Paterakis G., Popov A., Ratei R., Rodriguez C., Sajaroff E. O., Sala S., Samardzija G., Sartor M., Scarparo P., Sedek L., Slavkovic B., Solari L., Svec P., Szczepanski T., Taparkou A., Torrebadell M., Tzanoudaki M., Varotto E., Vernitsky H., Attarbaschi A., Schrappe M., Conter V., Biondi A., Felice M., Campbell M., Kiss C., Basso G., Dworzak M. N., Maurer-Granofszky, M, Schumich, A, Buldini, B, Gaipa, G, Kappelmayer, J, Mejstrikova, E, Karawajew, L, Rossi, J, Suzan, A, Agriello, E, Anastasiou-Grenzelia, T, Barcala, V, Barna, G, Batinic, D, Bourquin, J, Bruggemann, M, Bukowska-Strakova, K, Burnusuzov, H, Carelli, D, Deniz, G, Dubravcic, K, Feuerstein, T, Gaillard, M, Galeano, A, Giordano, H, Gonzalez, A, Groeneveld-Krentz, S, Hevessy, Z, Hrusak, O, Iarossi, M, Jakso, P, Prevodnik, V, Kohlscheen, S, Kreminska, E, Maglia, O, Malusardi, C, Marinov, N, Martin, B, Moller, C, Nikulshin, S, Palazzi, J, Paterakis, G, Popov, A, Ratei, R, Rodriguez, C, Sajaroff, E, Sala, S, Samardzija, G, Sartor, M, Scarparo, P, Sedek, L, Slavkovic, B, Solari, L, Svec, P, Szczepanski, T, Taparkou, A, Torrebadell, M, Tzanoudaki, M, Varotto, E, Vernitsky, H, Attarbaschi, A, Schrappe, M, Conter, V, Biondi, A, Felice, M, Campbell, M, Kiss, C, Basso, G, Dworzak, M, Maurer-Granofszky M., Schumich A., Buldini B., Gaipa G., Kappelmayer J., Mejstrikova E., Karawajew L., Rossi J., Suzan A. C., Agriello E., Anastasiou-Grenzelia T., Barcala V., Barna G., Batinic D., Bourquin J. -P., Bruggemann M., Bukowska-Strakova K., Burnusuzov H., Carelli D., Deniz G., Dubravcic K., Feuerstein T., Gaillard M. I., Galeano A., Giordano H., Gonzalez A., Groeneveld-Krentz S., Hevessy Z., Hrusak O., Iarossi M. B., Jakso P., Prevodnik V. K., Kohlscheen S., Kreminska E., Maglia O., Malusardi C., Marinov N., Martin B. M., Moller C., Nikulshin S., Palazzi J., Paterakis G., Popov A., Ratei R., Rodriguez C., Sajaroff E. O., Sala S., Samardzija G., Sartor M., Scarparo P., Sedek L., Slavkovic B., Solari L., Svec P., Szczepanski T., Taparkou A., Torrebadell M., Tzanoudaki M., Varotto E., Vernitsky H., Attarbaschi A., Schrappe M., Conter V., Biondi A., Felice M., Campbell M., Kiss C., Basso G., and Dworzak M. N.

Abstract

Monitoring of minimal residual disease (MRD) by flow cytometry (FCM) is a powerful prognostic tool for predicting outcomes in acute lymphoblastic leukemia (ALL). To apply FCM-MRD in large, collaborative trials, dedicated laboratory staff must be educated to concordantly high levels of expertise and their performance quality should be continuously monitored. We sought to install a unique and comprehensive training and quality control (QC) program involving a large number of reference laboratories within the international Berlin-Frankfurt-Münster (I-BFM) consortium, in order to complement the standardization of the methodology with an educational component and persistent quality control measures. Our QC and quality assurance (QA) program is based on four major cornerstones: (i) a twinning maturation program, (ii) obligatory participation in external QA programs (spiked sample send around, United Kingdom National External Quality Assessment Service (UK NEQAS)), (iii) regular participation in list-mode-data (LMD) file ring trials (FCM data file send arounds), and (iv) surveys of independent data derived from trial results. We demonstrate that the training of laboratories using experienced twinning partners, along with continuous educational feedback significantly improves the performance of laboratories in detecting and quantifying MRD in pediatric ALL patients. Overall, our extensive education and quality control program improved inter-laboratory concordance rates of FCM-MRD assessments and ultimately led to a very high conformity of risk estimates in independent patient cohorts.

Published
2021

22. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia

Author

Dworzak, M, Buldini, B, Gaipa, G, Ratei, R, Hrusak, O, Luria, D, Rosenthal, E, Bourquin, J, Sartor, M, Schumich, A, Karawajew, L, Mejstrikova, E, Maglia, O, Mann, G, Ludwig, W, Biondi, A, Schrappe, M, Basso, G, Dworzak, M, Buldini, B, Gaipa, G, Ratei, R, Hrusak, O, Luria, D, Rosenthal, E, Bourquin, J, Sartor, M, Schumich, A, Karawajew, L, Mejstrikova, E, Maglia, O, Mann, G, Ludwig, W, Biondi, A, Schrappe, M, and Basso, G

Subjects
standardization, flow cytometry, immunophenotyping, leukemia, pediatric, 2734, Histology, Cell Biology, Consensus, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Immunophenotyping, Phenotype, Acute Disease, Humans, Child
Abstract

Immunophenotyping by flow cytometry (FCM) is a worldwide mainstay in leukemia diagnostics. For concordant multicentric application, however, a gap exists between available classification systems, technologic standardization, and clinical needs. The AIEOP-BFM consortium induced an extensive standardization and validation effort between its nine national reference laboratories collaborating in immunophenotyping of pediatric acute lymphoblastic leukemia (ALL). We elaborated common guidelines which take advantage of the possibilities of multi-color FCM: marker panel requirements, immunological blast gating, in-sample controls, tri-partite antigen expression rating (negative vs. weak or strong positive) with capturing of blast cell heterogeneities and subclone formation, refined ALL subclassification, and a dominant lineage assignment algorithm able to distinguish “simple” from bilineal/“complex” mixed phenotype acute leukemia (MPAL) cases, which is essential for choice of treatment. These guidelines are a first step toward necessary inter-laboratory standardization of pediatric leukemia immunophenotyping for a concordant multicentric application. © 2017 International Clinical Cytometry Society.

Published
2018

30. Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Author

Locatelli, Franco, Valsecchi, M. G., Moricke, A., Zimmermann, M., Gruhn, B., Biondi, A., Kulozik, A. E., Silvestri, D., Bodmer, N., Putti, M. C., Burdach, S., Micalizzi, C., Teigler-Schlegel, A., Ritter, J., Pession, A., Cario, G., Bielack, S., Basso, G., Klingebiel, T., Vinti, L., Rizzari, C., Attarbaschi, A., Santoro, N., Parasole, R., Mann, G., Karawajew, L., Haas, O. A., Conter, V., Schrappe, M., Locatelli F. (ORCID:0000-0002-7976-3654), Locatelli, Franco, Valsecchi, M. G., Moricke, A., Zimmermann, M., Gruhn, B., Biondi, A., Kulozik, A. E., Silvestri, D., Bodmer, N., Putti, M. C., Burdach, S., Micalizzi, C., Teigler-Schlegel, A., Ritter, J., Pession, A., Cario, G., Bielack, S., Basso, G., Klingebiel, T., Vinti, L., Rizzari, C., Attarbaschi, A., Santoro, N., Parasole, R., Mann, G., Karawajew, L., Haas, O. A., Conter, V., Schrappe, M., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2017

31. Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Author

Locatelli, F, Valsecchi, M, Möricke, A, Zimmermann, M, Gruhn, B, Biondi, A, Kulozik, A, Silvestri, D, Bodmer, N, Putti, M, Burdach, S, Micalizzi, C, Teigler-Schlegel, A, Ritter, J, Pession, A, Cario, G, Bielack, S, Basso, G, Klingebiel, T, Vinti, L, Rizzari, C, Attarbaschi, A, Santoro, N, Parasole, R, Mann, G, Karawajew, L, Haas, O, Conter, V, Schrappe, M, Valsecchi, MG, Kulozik, AE, Putti, MC, Locatelli, F, Valsecchi, M, Möricke, A, Zimmermann, M, Gruhn, B, Biondi, A, Kulozik, A, Silvestri, D, Bodmer, N, Putti, M, Burdach, S, Micalizzi, C, Teigler-Schlegel, A, Ritter, J, Pession, A, Cario, G, Bielack, S, Basso, G, Klingebiel, T, Vinti, L, Rizzari, C, Attarbaschi, A, Santoro, N, Parasole, R, Mann, G, Karawajew, L, Haas, O, Conter, V, Schrappe, M, Valsecchi, MG, Kulozik, AE, and Putti, MC

Published
2017

33. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

Author

Dworzak, M, Gaipa, G, Ratei, R, Veltroni, M, Schumich, A, Maglia, O, Karawajew, L, Benetello, A, Pötschger, U, Husak, Z, Gadner, H, Biondi, A, Ludwig, W, Basso, G, Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, Karawajew L, Benetello A, Pötschger U, Husak Z, Gadner H, Ludwig WD, Basso G., BIONDI, ANDREA, Dworzak, M, Gaipa, G, Ratei, R, Veltroni, M, Schumich, A, Maglia, O, Karawajew, L, Benetello, A, Pötschger, U, Husak, Z, Gadner, H, Biondi, A, Ludwig, W, Basso, G, Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, Karawajew L, Benetello A, Pötschger U, Husak Z, Gadner H, Ludwig WD, Basso G., and BIONDI, ANDREA

Abstract

Background: Single-laboratory experience showed that flow cytometric (FCM) assessment of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) is feasible in most patients and gives independent prognostic information. It is, however, not known whether FCM analysis can reliably be standardized for multicentric application. Methods: An extensive standardization program was installed in four collaborating laboratories, which study FCM-MRD in children treated with the AIEOP-BFM-ALL 2000 protocol. This included methodological alignment, continuous quality monitoring, as well as personnel education by exchange and performance feed-back. Results: Blinded inter-laboratory tests of list-mode data interpretation concordance (n = 202 blood and bone marrow samples from follow-up during induction of 31 randomly selected patients of a total series of n = 395) showed a very high degree of inter-rater agreement among the four centers despite differences in cytometers and software usage (intraclass correlation coef.cient [ICC] 0.979 based on n = 800 single values). Lower concordance was reached with amounts of MRD below 0.1%. Comparing data from sample exchange experiments (n = 42 samples; ICC 0.98) and from independent patient cohorts from the four centers (regarding positive samples per time-point of follow-up as well as risk estimates) concordance was also good. Conclusion: MRD-evaluation by FCM in ALL can be standardized for reliable multicentric assessment in large trials. © 2008 Clinical Cytometry Society.

Published
2008

34. Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping

Author

Hrušák, O, Basso, Giuseppe, Ratei, R, Gaipa, G, Luria, D, Mejstříková, E, Karawajew, L, Buldini, Barbara, Rozenthal, E, Bourquin, Jp, Kalina, T, Sartor, M, Dworzak, Mn, and AIEOP BFM Flow Network

Subjects
Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Flow Cytometry, Immunophenotyping
Abstract

Flow cytometry is a valuable part in the routine diagnostics of acute leukemia (AL). Although internationally recognized definitions of main AL subsets are available, there is currently no consensus format for the short summary of clinical flow cytometry reports. Since clinical reports are too long for most database purposes, there is a need for a standardized format of their short summaries.The Associazione Italiana Ematologia Oncologia Pediatrica--Berlin Frankfurt Muenster (AIEOP-BFM) Flow Network that encompasses reference diagnostics laboratories in Australia, Austria, Czechia, Germany, Israel, Italy, and Switzerland have designed a pro-forma for the summary of flow cytometry results in the diagnosis of leukemia. The process involved several meetings and other communications, during which the group established a consensus on the essentials that lead to the diagnostic conclusions in childhood AL.The "Flow Diagnostics Essential (FDE) Code" is a result from an agreement within the AIEOP-BFM Flow Network. In a standardized format, it reports the extent of the infiltration by a malignant clone, followed by description antigen expression as strong, weak or negative, and a diagnostic conclusion.A consensus brief format (the "FDE Code") has been designed as a brief summary of the diagnostic immunophenotype of childhood AL. It is also applicable for the diagnostic investigation of other malignancies by flow cytometry. The FDE code may be included in the final clinical report and/or used in the setting of a multicenter clinical trial database.

Published
2014

40. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia

Author

Karawajew, L., primary, Dworzak, M., additional, Ratei, R., additional, Rhein, P., additional, Gaipa, G., additional, Buldini, B., additional, Basso, G., additional, Hrusak, O., additional, Ludwig, W.-D., additional, Henze, G., additional, Seeger, K., additional, von Stackelberg, A., additional, Mejstrikova, E., additional, and Eckert, C., additional

Published
2015
Full Text
View/download PDF

44. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia

Author

Gaipa, G, Cazzaniga, G, Valsecchi, M, Panzer Grümayer, R, Buldini, B, Silvestri, D, Karawajew, L, Maglia, O, Ratei, R, Benetello, A, Sala, S, Schumich, A, Schrauder, A, Villa, T, Veltroni, M, Ludwig, W, Conter, V, Schrappe, M, Biondi, A, Dworzak, M, Basso, G, VALSECCHI, MARIA GRAZIA, Ludwig, WD, BIONDI, ANDREA, Dworzak, MN, Basso, G., Gaipa, G, Cazzaniga, G, Valsecchi, M, Panzer Grümayer, R, Buldini, B, Silvestri, D, Karawajew, L, Maglia, O, Ratei, R, Benetello, A, Sala, S, Schumich, A, Schrauder, A, Villa, T, Veltroni, M, Ludwig, W, Conter, V, Schrappe, M, Biondi, A, Dworzak, M, Basso, G, VALSECCHI, MARIA GRAZIA, Ludwig, WD, BIONDI, ANDREA, Dworzak, MN, and Basso, G.

Abstract

Background Flow cytometric analysis of leukemia-associated immunophenotypes and polymerase chain reaction-based amplification of antigen-receptor genes rearrangements are reliable methods for monitoring minimal residual disease. The aim of this study was to compare the performances of these two methodologies in the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Design and Methods Polymerase chain reaction and flow cytometry were simultaneously applied for prospective minimal residual disease measurements at days 15, 33 and 78 of induction therapy on 3565 samples from 1547 children with acute lymphoblastic leukemia enrolled into the AIEOP-BFM ALL 2000 trial. Results The overall concordance was 80%, but different results were observed according to the time point. Most discordances were found at day 33 (concordance rate 70%) in samples that had significantly lower minimal residual disease. However, the discordance was not due to different starting materials (total versus mononucleated cells), but rather to cell input number. At day 33, cases with minimal residual disease below or above the 0.01% cut-off by both methods showed a very good outcome (5-year event-free survival, 91.6%) or a poor one (5-year eventfree survival, 50.9%), respectively, whereas discordant cases showed similar event-free survival rates (around 80%). Conclusions Within the current BFM-based protocols, flow cytometry and polymerase chain reaction cannot simply substitute each other at single time points, and the concordance rates between their results depend largely on the time at which they are used. Our findings suggest a potential complementary role of the two technologies in optimizing risk stratification in future clinical trials.

Published
2012

46. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group

Author

Dworzak, M, Gaipa, G, Schumich, A, Maglia, O, Ratei, R, Veltroni, M, Husak, Z, Basso, G, Karawajew, L, Gadner, H, Biondi, A, Dworzak, MN, BIONDI, ANDREA, Dworzak, M, Gaipa, G, Schumich, A, Maglia, O, Ratei, R, Veltroni, M, Husak, Z, Basso, G, Karawajew, L, Gadner, H, Biondi, A, Dworzak, MN, and BIONDI, ANDREA

Abstract

Background: Changes of antigen expression on residual blast cells of acute lymphoblastic leukemia (ALL) occur during induction treatment. Many markers used for phenotyping and minimal residual disease (MRD) monitoring are affected. Glucocorticoid (GC)-induced expression modulation has been causally suspected, however, subclone selection may also cause the phenomenon. Methods: We investigated this by following the phenotypic evolution of leukemic cells with flow cytometry from diagnosis to four time points during and after GC containing chemotherapy in the 20 (of 360 consecutive) B-cell precursor patients with ALL who had persistent MRD throughout. Results: The early expression changes of CD10 and CD34 were reversible after stop of GC containing chemotherapy. Modulation of CD20 and CD45 occurred mostly during the GC phase, whereas CD11a also changed later on. Blast cells at diagnosis falling into gates designed according to "shifted" phenotypes from follow-up did not form clusters and were frequently less numerous than later on. Conclusions: Our data support the idea that drug-induced modulation rather than selection causes the phenomenon. The good message for MRD assessment is that modulation is transient in at least two (CD10 and CD34) of the five prominent antigens investigated and reverts to initial aberrant patterns after stop of GC therapy, whereas CD20 expression gains new aberrations exploitable for MRD detection. © 2010 Clinical Cytometry Society.

Published
2010

47. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

Author

Zaliova, M, primary, Zimmermannova, O, additional, Dörge, P, additional, Eckert, C, additional, Möricke, A, additional, Zimmermann, M, additional, Stuchly, J, additional, Teigler-Schlegel, A, additional, Meissner, B, additional, Koehler, R, additional, Bartram, C R, additional, Karawajew, L, additional, Rhein, P, additional, Zuna, J, additional, Schrappe, M, additional, Cario, G, additional, and Stanulla, M, additional

Published
2013
Full Text
View/download PDF

48. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

Author

Cario, G., primary, Rhein, P., additional, Mitlohner, R., additional, Zimmermann, M., additional, Bandapalli, O. R., additional, Romey, R., additional, Moericke, A., additional, Ludwig, W.-D., additional, Ratei, R., additional, Muckenthaler, M. U., additional, Kulozik, A. E., additional, Schrappe, M., additional, Stanulla, M., additional, and Karawajew, L., additional

Published
2013
Full Text
View/download PDF

50. Development of an enzyme immunoassay for the measurement of human tumour necrosis factor-alpha (hTNF-alpha) using bispecific antibodies to hTNF-alpha and horseradish peroxidase

Author

Nadia Berkova, Karawajew L, Korobko V, Behrsing O, Micheel B, Shamborant O, Stukatcheva E, and Shingarova L

Subjects
Hybridomas, Time Factors, Base Sequence, Tumor Necrosis Factor-alpha, Antibodies, Bispecific, Molecular Sequence Data, Humans, Enzyme-Linked Immunosorbent Assay, Sensitivity and Specificity, Horseradish Peroxidase, Recombinant Proteins
Abstract

The cytokine tumour necrosis factor-alpha (TNF-alpha) is involved in several pathological processes, and human recombinant TNF-alpha (hrTNF-alpha) is available for testing in preclinical and clinical research. The purpose of this work was the creation of tetradomas producing bispecific anti-hTNF-alpha/anti-HRP (horseradish peroxidase) antibodies and the development of a rapid and sensitive solid-phase enzyme immunoassay. Monoclonal antibodies obtained against hrTNF-alpha could recognize both natural and recombinant hTNF-alpha. The four chosen hybridomas produced IgG1 with an affinity constant of the order of 10(-9) M. Three of them recognized different epitopes. The clone selected for fusion with the hybridoma producing anti-HRP antibodies secreted antibodies against portion 30-50 of the hTNF-alpha N-terminal amino acid residues as found by Western-blot analysis with mutant and chimaeric proteins. The tetradoma producing bispecific anti-hTNF-alpha/anti-HRP antibodies was identified using a fluorescence-activated cell sorter. Bispecific antibodies were isolated by hydroxyapatite chromatography. A sandwich ELISA was developed: one of the monoclonal anti-TNF-alpha antibodies was absorbed to the solid phase as the catcher and was detected by a bispecific anti-hTNF-alpha/anti-HRP antibody. The detection limit of the assay was 1 ng/ml. With such ELISA, the level of hTNF-alpha could be conveniently estimated in different samples containing either natural or recombinant hTNF-alpha in an experimental environment or in clinical trials.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results